Efficacy of 5-hydroxytryptamine-3 (5-HT3) antagonists adjuvant therapy for moderate to severe obsessive–compulsive disorder: A systematic review and meta-analysis of randomized clinical trials

Abstract

Abstract Background: obsessive–compulsive disorder (OCD) is the fourth most common mental disorder, and selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of its pharmacological treatment. About 40-60% of the cases are treatment-refractory, and this makes searching for second-line treatment necessary. 5-hydroxytryptamine-3 (5-HT3) antagonists are among the many medications that have been used in augmentation with SSRIs. Objectives: In this systematic review and meta-analysis, we assessed the efficacy of 5-HT3 receptor antagonists in augmentation with SSRIs in treating moderate to severe OCD. Methods: We searched PubMed, Web of Science, Scopus, Cochrane library, and Google Scholar for relevant trials published up to December 2022. The effect size was the mean difference in Yale-Brown obsessive compulsive scale (Y-BOCS) scores before and after receiving 5-HT3 receptor antagonist drugs in augmentation with SSRIs in moderate to severe OCD patients. Results: We included 6 randomized-controlled trails (RCTs) with 334 patients assessing the effect of the augmentation of SSRIs with ondansetron, granisetron, and tropisetron on treating moderate to severe OCD. Our results were in favor of the experimental group in total (Z=8.37, P<0.00001), in the compulsion subgroup (Z=5.22, P<0.00001), and in the obsession subgroup (Z=8.33, P<0.00001). They are well-tolerated, and have mild side effects and do not result in withdrawal. Conclusion: Augmentation of 5HT-3 antagonists with SSRIs can be beneficial in treating moderate to severe OCD. Further multi-center trials under adequate conditions in longer periods are needed to help come up with a comprehensive action plan.